* Aikido Pharma Inc AIKI.OQ AIKI.O is expected to report
results on May 9 (estimated).
* Refinitiv's mean analyst estimate for Aikido Pharma Inc
is for
a loss of 2 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Aikido
Pharma Inc
is $2, above its last closing price of $0.35.
This summary was machine generated May 6 at 18:34 GMT. All
figures in US dollars unless otherwise stated